Back to Search Start Over

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

Authors :
Tio, Martin
Wang, Xuan
Carlino, Matteo S.
Shivalingam, Brindha
Fogarty, Gerald B.
Guminski, Alexander D.
Lo, Serigne
Hong, Angela M.
Menzies, Alexander M.
Long, Georgina V.
Source :
Pigment Cell & Melanoma Research. Jul2018, Vol. 31 Issue 4, p509-515. 7p.
Publication Year :
2018

Abstract

Summary: Historically, the prognosis of patients with melanoma brain metastases is poor, with median overall survival (OS) of 4‐6 months. Little is known of OS in the era of modern systemic therapies and local therapy with stereotactic radiosurgery (SRS) or surgery. Patients diagnosed with melanoma brain metastases at Melanoma Institute Australia from January 2011 to December 2014 were included. OS and prognostic factors were analysed using Cox regression and Kaplan‐Meier survival analyses.355 patients were included. The median OS was 7.1 months (95% confidence interval [CI] 6.0‐8.1). Median OS differed by treatment modality: systemic therapy and SRS and/or surgery 14.9 months (95% CI 10.7‐19.0), SRS and/or surgery with or without whole brain radiotherapy (WBRT) 6.4 months (95% CI 5.4‐7.5), systemic therapy 5.4 months (95% CI 3.1‐7.7), systemic therapy and WBRT 5.2 months (95% CI 4.1‐6.4), WBRT 4.4 months (95% CI 2.4‐6.3), and best supportive care 1.8 months (95% CI 1.2‐2.3). OS for patients with melanoma brain metastases appears improved in the modern era, particularly for patients who are candidates for systemic therapy with SRS and/or surgery. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17551471
Volume :
31
Issue :
4
Database :
Academic Search Index
Journal :
Pigment Cell & Melanoma Research
Publication Type :
Academic Journal
Accession number :
130287486
Full Text :
https://doi.org/10.1111/pcmr.12682